Human medicines European public assessment report (EPAR): Epruvy (previously Ranibizumab Midas), ranibizumab, Date of authorisation: 19/09/2024, Revision: 5, Status: Authorised

International Coalition of Medicines Regulatory Authorities (ICMRA)

Global regulators call for advancing alternatives to animal testing across the medicine lifecycle

Executive Director speech at EMA women’s health multi-stakeholder workshop

EudraVigilance: electronic reporting

Human medicines European public assessment report (EPAR): Pomalidomide Teva, pomalidomide, Date of authorisation: 14/11/2024, Revision: 3, Status: Authorised

Minutes of PRAC meeting on 6-9 July 2026

Human medicines European public assessment report (EPAR): Denbrayce, denosumab, Date of authorisation: 26/06/2025, Revision: 4, Status: Authorised

Human medicines European public assessment report (EPAR): Comirnaty, COVID-19 mRNA vaccine, Date of authorisation: 21/12/2020, Revision: 63, Status: Authorised

Women are missing from medicines development: EMA’s roadmap for change